In this CME activity, Susana M. Campos, MD, MS, MPH, reviews some of the recent clinical developments in the treatment of patients with advanced ovarian cancer with PARP inhibitors. We welcome you to learn more about the updated data from key clinical studies of PARP inhibitor maintenance therapy in advanced ovarian cancer, and the implications of the results on the current and emerging concepts in ovarian cancer clinical practice.
Course Credit:
0.50 AMA PRA Category 1 CreditsTM
Dates:
Opens: 2021-09-29
Closes: 2022-09-29
Target Audience:
This activity is intended for medical oncologists, gynecologic oncologists, and other healthcare professionals involved in the treatment of patients with advanced ovarian cancer.
This educational activity is supported by an educational grant from GlaxoSmithKline.
Accreditation and Certification
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Additional Content Planners
Krithika Subramanian, PhD (Medical Writer)No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Susana Campos, MD, MS, MPH
Assistant Professor, Medicine
Harvard Medical School
Boston, Massachusetts
Presenting Faculty
Downloads
Learning Objectives
- Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors in ovarian cancer
- Incorporate evidence-based research into clinical practice to improve patient outcomes
Faculty Disclosures
Susana Campos, MD, MS, MPH
Advisory Board: AstraZeneca, Eisai, GlaxoSmithKline